Pharming Group N.V.

OTCPK:PHGU.F Stock Report

Market Cap: US$517.2m

Pharming Group Valuation

Is PHGU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHGU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHGU.F ($0.75) is trading below our estimate of fair value ($7.7)

Significantly Below Fair Value: PHGU.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHGU.F?

Key metric: As PHGU.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PHGU.F. This is calculated by dividing PHGU.F's market cap by their current revenue.
What is PHGU.F's PS Ratio?
PS Ratio1.8x
SalesUS$285.75m
Market CapUS$517.24m

Price to Sales Ratio vs Peers

How does PHGU.F's PS Ratio compare to its peers?

The above table shows the PS ratio for PHGU.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
RIGL Rigel Pharmaceuticals
2.9x13.0%US$458.7m
URGN UroGen Pharma
5.9x42.7%US$502.6m
TNGX Tango Therapeutics
9.4x13.5%US$421.1m
IRWD Ironwood Pharmaceuticals
1.4x10.0%US$550.5m
PHGU.F Pharming Group
1.8x9.7%US$492.8m

Price-To-Sales vs Peers: PHGU.F is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (4.9x).

Price to Sales Ratio vs Industry

How does PHGU.F's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.4x21.4%
PHGU.F Pharming Group
 1.8x9.7%US$517.24m
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
PHGU.F 1.8xIndustry Avg. 9.4xNo. of Companies128PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.4x28.3%
PHGU.F Pharming Group
 1.8x73.2%US$517.24m
No more companies

Price-To-Sales vs Industry: PHGU.F is good value based on its Price-To-Sales Ratio (1.8x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is PHGU.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHGU.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHGU.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PHGU.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.74
US$1.96
+162.8%
12.0%US$2.28US$1.74n/a3
Nov ’25n/a
US$1.97
0%
11.1%US$2.28US$1.79n/a3
Oct ’25n/a
US$1.99
0%
12.6%US$2.34US$1.79n/a3
Sep ’25n/a
US$1.99
0%
12.6%US$2.34US$1.79n/a3
Aug ’25US$0.80
US$2.02
+152.3%
12.0%US$2.26US$1.78n/a2
Jul ’25US$0.81
US$2.02
+150.5%
12.0%US$2.26US$1.78n/a2
Jun ’25US$0.93
US$2.09
+124.9%
10.4%US$2.27US$1.78n/a3
May ’25US$0.95
US$2.13
+123.2%
5.4%US$2.24US$1.97n/a3
Apr ’25n/a
US$2.17
0%
5.4%US$2.28US$2.01n/a3
Mar ’25US$1.13
US$1.94
+71.6%
9.0%US$2.21US$1.72n/a4
Feb ’25US$1.29
US$2.06
+59.9%
10.7%US$2.29US$1.75n/a4
Jan ’25n/a
US$1.98
0%
9.2%US$2.19US$1.71n/a4
Dec ’24n/a
US$1.98
0%
9.2%US$2.19US$1.71n/a4
Nov ’24n/a
US$1.94
0%
8.9%US$2.16US$1.69n/a4
Oct ’24US$1.30
US$2.04
+56.8%
8.8%US$2.24US$1.75n/a4
Sep ’24US$1.23
US$2.04
+65.8%
8.8%US$2.24US$1.75n/a4
Aug ’24n/a
US$2.04
0%
11.1%US$2.30US$1.68US$0.804
Jul ’24US$1.18
US$2.06
+75.5%
5.4%US$2.21US$1.94US$0.813
Jun ’24US$1.23
US$2.13
+72.8%
5.5%US$2.24US$1.97US$0.933
May ’24n/a
US$2.13
0%
5.5%US$2.24US$1.96US$0.953
Apr ’24US$1.26
US$2.11
+67.8%
5.5%US$2.22US$1.95n/a3
Mar ’24US$1.23
US$1.90
+54.5%
6.7%US$2.03US$1.77US$1.132
Feb ’24US$1.43
US$1.77
+24.0%
6.7%US$1.89US$1.65US$1.292
Jan ’24n/a
US$1.77
0%
6.7%US$1.89US$1.65n/a2
Dec ’23US$1.21
US$1.77
+46.6%
6.7%US$1.89US$1.65n/a2
Nov ’23n/a
US$1.77
0%
6.7%US$1.89US$1.65n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%